Nanjing Vazyme Biotech Co (SHSE:688105) Debt-to-Equity : 0.27 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nanjing Vazyme Biotech Co Debt-to-Equity?

Nanjing Vazyme Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥935 Mil. Nanjing Vazyme Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥147 Mil. Nanjing Vazyme Biotech Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥3,998 Mil. Nanjing Vazyme Biotech Co's debt to equity for the quarter that ended in Mar. 2024 was 0.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nanjing Vazyme Biotech Co's Debt-to-Equity or its related term are showing as below:

SHSE:688105' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.09 Max: 0.33
Current: 0.27

During the past 7 years, the highest Debt-to-Equity Ratio of Nanjing Vazyme Biotech Co was 0.33. The lowest was 0.02. And the median was 0.09.

SHSE:688105's Debt-to-Equity is ranked worse than
62.48% of 1058 companies
in the Biotechnology industry
Industry Median: 0.14 vs SHSE:688105: 0.27

Nanjing Vazyme Biotech Co Debt-to-Equity Historical Data

The historical data trend for Nanjing Vazyme Biotech Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Vazyme Biotech Co Debt-to-Equity Chart

Nanjing Vazyme Biotech Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.18

0.03

0.02

0.10

0.32

Nanjing Vazyme Biotech Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.26	0.33	0.33	0.32	0.27

Competitive Comparison of Nanjing Vazyme Biotech Co's Debt-to-Equity

For the Biotechnology subindustry, Nanjing Vazyme Biotech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Vazyme Biotech Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanjing Vazyme Biotech Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nanjing Vazyme Biotech Co's Debt-to-Equity falls into.

Nanjing Vazyme Biotech Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nanjing Vazyme Biotech Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1180.126	+	106.891)	/	4029.388
	=	0.32

Nanjing Vazyme Biotech Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(934.917	+	147.287)	/	3998.151
	=	0.27

Nanjing Vazyme Biotech Co (SHSE:688105) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nanjing Vazyme Biotech Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nanjing Vazyme Biotech Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Vazyme Biotech Co (SHSE:688105) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanjing Vazyme Biotech Co Ltd (SHSE:688105) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000

Website

http://www.vazyme.com

Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.

Nanjing Vazyme Biotech Co (SHSE:688105) Headlines

No Headlines